Company: ZVRA
Filing Date: 2025-04-10
Form Type: PREC14A
Source: 0000897069-25-000784
Chunk: 11

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-04-10
Form: PREC14A
Chunk 11
---
 director’s successor is duly elected and qualified. The current class structure is as follows: Class I, whose term will expire at the Annual Meeting and, if elected at the Annual Meeting, whose subsequent term will expire at the 2028 annual meeting of stockholders; Class II, whose current term will expire at the 2026 annual meeting of stockholders; and Class III, whose term will expire at the 2027 annual meeting of stockholders. The current Class I directors are Wendy Dixon, Ph.D. and Tamara A. Favorito; the current Class II directors are John B. Bode, Douglas W. Calder, and Corey Watton; and the current Class III directors are Thomas D. Anderson, Neil F. McFarlane and Alvin Shih, M.D. Mr. Mangless is seeking your proxy to vote for the election to the Board of Directors of two highly qualified nominees - Travis C. Mickle, Ph.D. and Arthur C. Regan.If elected as a director of the Company, Mr. Regan would be, an “independent director” within the meaning of (i) applicable Nasdaq listing standards applicable to board composition and (ii) Section 301 of the Sarbanes-Oxley Act of 2002. If elected as a director of the of the Company, Dr. Mickle would not qualify as an “independent director” within the above meaning by virtue of his having been an employee of the Company within the last three years. The Proponent is not seeking to acquire control of the Company. The Proponent has not paid the Nominees in connection with their intended nomination and there are no agreements, arrangements or understandings with respect to any decisions they would make as directors if elected. Instead, the Proponent’s sole interest is in electing a board with the qualifications and ability to facilitate necessary and meaningful changes in order to maximize long-term value for the Company’s stockholders. Biographical Information Regarding the Nominees The following information concerning the age, principal occupation and business experience during the last five years, and current public directorships of each of the Nominees. Travis C. Mickle, PhD, 52, currently serves as a Senior Advisor and Consultant, providing strategic guidance on FDA interactions, regulatory filings, drug development, and business transactions for pharmaceutical and biotechnology companies. Since 2022, he has consulted for organizations including Zevra, Corium, and Sydnexis, advising on regulatory approvals, investment strategies, and corporate struct